赛克洛 (His-Pro):在脂肪肝炎的管理中又迈出了一步
Alessia De Masi1, Xiaoxu Li1, Dohyun Lee2
1Laboratory of Integrative Systems Physiology, Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
JHEP reports : innovation in hepatology
|August 21, 2023
概括
在非酒精性脂肪性肝病 (NAFLD) 的小鼠模型中,循环歇斯蒂丁- (CHP) 有效地降低了肝脂肪,炎症和纤维化. 这种天然化合物显示出作为一种新的治疗策略来管理NAFLD进展的希望.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 非酒精性脂肪肝 (NAFLD) 和脂肪肝炎 (NASH) 是普遍存在的全球健康问题.
- 目前对NAFLD/NASH的药理疗法有限,需要新的治疗策略.
- 环西丁- (His-Pro) (CHP) 是一种天然存在的化合物,具有抗炎性质和有利的安全性.
研究的目的:
- 评估CHP在已建立的小鼠模型中对肝病进展,特别是纤维化,的保护作用.
- 研究CHP对NAFLD/NASH的关键病理特征的影响,包括肥胖症,炎症和纤维化.
- 在肝病发育过程中识别CHP调节的分子通路.
主要方法:
- 利用两种不同的小鼠模型:一种通过热中性住房和西方饮食模仿饮食NAFLD/NASH,另一种通过四化碳注射诱导纤维化.
- 评估了CHP治疗对脂质积累,全身炎症,高血糖症,肥胖症,炎症和纤维化通过组织病理学和肝脏转录学的影响.
- 研究了细胞外信号调节激酶 (ERK) 途径在调节细胞对CHP的反应中的作用.
主要成果:
- 慢性代谢治疗显著限制了脂质积累,减少了全身炎症,并预防了高血糖症.
- 组织病理学和转录学揭示了降低脂肪和显著的保护,防止炎症和纤维化发展.
- 在预防和治疗环境中,CHP表现出有效性,改善了多种肝病标志物.
结论:
- 在临床前模型中,CHP有效地减轻了NAFLD的进展,减少了关键的病理特征.
- 该化合物的减轻肥胖症,纤维化和炎症的能力将其定位为NAFLD管理的有希望的候选人.
- 这些发现支持在临床研究中对CHP进行进一步的研究,以研究潜在的NAFLD治疗.
相关概念视频
01:29Chronic Pancreatitis II: Collaborative Care
113
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
113
01:17Hepatic Drug Excretion: Enterohepatic Cycling
1.6K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.6K
01:24Cystic Fibrosis: Management
194
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
194
01:24Chronic Pancreatitis I: Introduction
112
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
112